Treatment for advanced bile duct and pancreatic cancers
Treatments studied
Part of Cancer clinical trials.
This trial is studying a new drug, telisotuzumab adizutecan, in combination with other treatments for advanced bile duct or pancreatic cancers. The goal is to see if the combination helps control the cancer. It's designed for people who are relatively active and can do their daily tasks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult with advanced bile duct or pancreatic cancer.
- Have tumors that can be measured with imaging tests (like CT scans).
- Have a performance status of 0 or 1, meaning you are up and about and can do light activities.
- Not have had certain lung conditions (interstitial lung disease or inflammation) recently.
- Not have had major surgery within the past month.
- Not have had prior treatment that targets the c-MET protein.
- Recover from any side effects of previous therapies, except for hair loss.
- Not be pregnant or breastfeeding.
- If you can have children, you need to follow the birth control rules in the study.
- Be willing and able to follow all the study rules and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
This trial tests a new targeted drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for people with advanced pancreatic cancer that has spread. The goal is to see if this combination works better than current treatments.
This study tests a new treatment for people with stage 4 pancreatic cancer who haven't yet had any treatment for advanced disease. The goal is to see if the new treatment can help shrink or control the cancer.
This trial tests a new drug for pancreatic cancer that has spread or come back after at least one prior treatment. The drug targets a protein on cancer cells to help stop tumor growth.
This trial tests whether adding bortezomib and an immunotherapy drug to standard chemotherapy can help people with pancreatic cancer that has spread to other organs. It is for patients who have not had treatment or whose cancer has worsened after gemcitabine-based chemotherapy.
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.